Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Oct 1, 2014

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient who have given their written consent in a free and informed consent
• • Patient followed for inflammatory bowel disease (Crohn's disease, ulcerative colitis or indeterminate colitis), and treated for at least 3 months by immunosuppressive therapy and /or biotherapies and in clinical remission for at least 3 months
• • Patient agreeing to participate in the study throughout its duration and accepting the procedures related to the study
• • Contraception that the investigator judges effective for the first 12 months of the trial, with a negative pregnancy test
• • Women not planning to become pregnant in the 12 months following inclusion (M0)
• • Patient with social coverage
• Exclusion Criteria:
• • Patients vaccinated against pneumo23 for less than 5 years
• • Other vaccination during the month before inclusion
• • Patient develops a febrile illness (at least 37 ° C 5 measured orally) or acute infection in the week before vaccination
• • The patient has a flare up of IBD the day of vaccination (Harvey-Brasdshaw score of at least 6 or CDAI \> 220 for Crohn's disease or Mayo Clinic score of at least 4 for UC and indeterminate colitis)
• • Patients with an ongoing pregnancy the day of vaccination
• • Patient with a known history of neuropathy as Guillain-Barré syndrome.
• • Patients with known infection with HIV and / or HBV (HBsAg positive) and / or HCV
• • Patient with other severe immune deficiency
• • Patients who received immunoglobulin infusions of blood products, or of monoclonal antibodies (except anti-TNF) in the 3 months prior to vaccination
• • Patient institutionalized, or deprived of liberty administrative or judicial
• • Patients treated without immunosuppressive therapy or biotherapies